Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the stock.

ONCT has been the topic of several other reports. Northland Securities reissued a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday, September 12th. HC Wainwright lowered their price target on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Capmk cut shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Oncternal Therapeutics Stock Performance

Shares of ONCT stock opened at $0.53 on Thursday. The firm’s 50-day moving average is $1.23 and its 200-day moving average is $4.43. The stock has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.17. Oncternal Therapeutics has a 52-week low of $0.53 and a 52-week high of $13.14.

Hedge Funds Weigh In On Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.